• The document is a regulatory filing containing the transcript of the Q2 and H1 FY27 Earnings Conference Call held on November 04, 2026. The event was an earnings call hosted by BNP Paribas to discuss quarterly results and provide a strategic update.
  • The conference call was held on Wednesday, November 04, 2026. The specific time was not mentioned in the transcript, but it was referred to as a "good morning" event.
  • The stated purpose of the event was to discuss the company's financial and operational performance for Q2 and H1 FY27, provide strategic updates, and address analyst questions.
  • The meeting was scheduled after the earnings announcement, as it discusses quarterly results that have already been reported.
  • Management participants included:
  • Ms. Ameera Shah – Chairperson and Whole-Time Director
  • Mr. Surendran Chemmenkotil – Managing Director
  • Mr. Sameer Patel – Chief Financial Officer
  • Mr. Mohan Menon – Chief Marketing Officer
  • SGA – Investor Relations

The call was moderated by Mr. Tausif Shaikh from BNP Paribas.

  • The company indicated that the transcript was being made available on the stock exchanges and the company's website (www.metropolisindia.com). The audio recording was also uploaded on the stock exchanges on November 04, 2026.
  • The company did not include specific compliance language about unpublished price sensitive information (UPSI) in this transcript.
  • Financial highlights discussed included:
  • Q2 FY27 revenue: INR 497 crores, growing 16% YoY
  • H1 FY27 revenue growth: 16.2% YoY
  • Q2 EBITDA: INR 135 crores, growing 24% YoY
  • Q2 EBITDA margin: 27.2% (180 bps expansion)
  • Q2 PAT: INR 75 crores, growing 43% YoY
  • Q2 PAT margin: 15.2% (290 bps expansion)
  • Patient volume growth: 10% YoY
  • Test volume growth: 11% YoY
  • B2C revenue growth: 17% YoY
  • B2B revenue growth: 15% YoY
  • TruHealth growth: 20% YoY (17% of revenue)
  • Specialty testing growth: 20% YoY (40% of revenue)
  • Cash and liquid investments: INR 348 crores as of September 30, 2026
  • Forward-looking statements and strategic themes included:
  • Expectation to continue similar growth and margin trajectory for the rest of the year
  • Plans for potential price increase in Q4 FY27 or early next year
  • Focus on accelerating center additions, B2B partnerships, and Tier 2/3 market expansion
  • Completion of laboratory platform transition in Q3 FY27
  • Rollout of new technology platforms including CRM, dynamic pricing engine, and sales app
  • Continued evaluation of M&A opportunities, particularly in North India

Additional Notes Section

  • The document was submitted as a regulatory filing to BSE Limited and National Stock Exchange of India Limited, with the transcript as an enclosure.
  • The transcript contains detailed financial data including revenue figures, growth rates, margin percentages, and volume metrics as presented during the earnings call.
  • The transcript includes a full question-and-answer session with analysts from various brokerage firms including PhillipCapital, Banyan Tree Advisors, Emkay, Nuvama, JM Financial, Goldman Sachs, Investec, and Centrum Broking.
  • The management discussed specific operational initiatives including the Insta60 service (60-minute home visit service) launched in Mumbai and Chennai, with plans to expand to Bangalore.